Happy New Year!

Since the launch of the "4+7" drug centralized procurement pilot in 2018, six rounds have been carried out.
The procurement content has expanded from oral dosage forms to injection dosage forms, and from chemical drugs to biological drugs.
The variety and quantity are constantly making breakthroughs, covering Drugs in many fields such as hypertension, diabetes, coronary heart disease, digestive tract diseases, malignant tumors, and rare diseases have been used, and the price of the selected products has dropped by more than half on average
.
Through the principle of exchanging price for quantity, centralized procurement has effectively suppressed the problem of inflated drug prices and brought real benefits to patients.
At the same time, it has further forced pharmaceutical companies to innovate and upgrade, and put more energy into product development and quality improvement.
on
.
Not only medicines, but also the centralized procurement of high-value medical consumables has also been launched.
Products including coronary stents, artificial joints and other products have been integrated into centralized procurement varieties, and the price drop has continued to increase, further reducing the cost burden of patients
.
It is reported that under the background of the continuous advancement of the reform of centralized procurement of drugs and high-value medical consumables, as of the end of 2021, a total of 260 billion yuan in medical insurance and patient expenditures have been saved
.
New Year's Gospel to! According to news on January 10, the next step is to promote the normalization and institutionalization of centralized and volume-based procurement and accelerate the expansion of coverage, and continue to reduce the price of medicines to benefit patients
.
According to the key content of the centralized procurement work in 2022, it mainly includes four aspects.
First, focusing on chronic diseases and common diseases, continue to promote the centralized procurement of drugs at the national level, and carry out provincial or inter-provincial drug procurement for drugs outside the national centralized procurement.
Alliance Procurement
.
By the end of 2022, a total of more than 350 drugs will be collected in each province at the national and provincial levels
.
It is understood that with the acceleration of the pace of life, changes in eating habits, and aggravation of aging, the incidence of chronic diseases in China continues to rise, and the number of patients continues to increase
.
According to reports, there are currently more than 200 million people with hypertension in China, and an increase of 10 million people every year; 92.
4 million people with diabetes, and 140 million people with elevated blood sugar; more than 200 million people with cardiovascular and cerebrovascular diseases
.
Because patients with chronic diseases need to take long-term medication, there are many burdens, including the burden of drug costs and psychological burden
.
With the normalization of centralized procurement, the price of more chronic disease drugs will be reduced, which will help to further reduce the burden on patients and improve the happiness index of patients.

.
Second, gradually expand the coverage of centralized procurement of high-value medical consumables, and conduct centralized procurement at the national and provincial levels for orthopedic consumables, drug balloons, and dental implants that are of concern to the public
.
A few days ago, the state-organized joint procurement platform for medical consumables has issued the "Notice on Carrying out Centralized Maintenance of Orthopaedic External Fixation Medical Consumables Information" and "On Carrying Out Orthopedic Trauma Medical Consumables Associated with Twelve Provinces Orthopedic Trauma Medical Consumables Alliance with Volume Procurement" Notice of Directory Work
.
It is reported that enterprises related to spinal medical consumables will receive digital certificates before January 14
.
In addition, the collection of dental implants will also be accelerated
.
Third, ensure the long-term stable supply of the selected drugs and consumables, strengthen supervision, and ensure that the price of the selected products does not deteriorate
.
Medical institutions should give reasonable priority to the use of the selected products
.
Fourth, implement the policy of retaining the balance of medical insurance funds for centralized procurement, promote the reform of the salary system, reasonably increase the income of medical staff, and better mobilize their enthusiasm
.
Under the new situation of centralized procurement, the industry expects that pharmaceutical companies will also accelerate the pace of transformation, from traditional generic drugs to high-end generic drugs or innovative drugs, the entire industry reshuffle is accelerated
.